৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Indications
Nytanco lin indicated for th trwtrnant of major dapracslve disordar (4DOj In aduits.
Pharmacology
The machaniern of the antidepreacan affact of Vartcastine le not fully understsod, but it ie thought to be mlated to its anhancamant of sarstonargic actvity iin the cantral narvous system theough Inhbition of the
muptaks of sarstanin (5-HT]. it alas ha anvaral other activitas including 5-HT3 rcaptor antaganiem and 5-HTSA mcaphor aganiam.
Dosage & Administration
Rscommanded dese: Tha nacommended starting doas it 10 mg adminisared arallly onen dally without regard to maale. The doaage should then be inereaned to 20 mg/ay. an tolerated. Tha affcacy and safety of douns
abowe 20 mg/day hawe not ban waluated in controllad diinica triale. A daon decrwss don to 5mg/day may ba conddand far patere wha do nat tolarate highar doass. Tha lowast affective doun of 5 mg/tay should
aiwys be uted a tha eariing doun for aldady patiarie [>65 years of agn].
Maintenanca dena: Far MDD, Varticustir can be administared for saveral months or langer. For a long pared us pasents thould be re-wvaluabed ia amsees tha usfunass of the druge forindwidual patlants.
Discontinuaton treatmant. Ahough Vorlicontne can be abruptly discontinund, in placabo-contraled trias patere apariancnd tranant adverse racone suc an heacache and muncle tanson following abrupt
discontinuation af Vorticotin 15 mg/day or 20 mg/day. To awaid than adverss reaction. it ic racormended tht the does should be decreaced ts 10 mg/day for one wnnk bafore full discontinuaton of Vortlocstine 15
mgiday or 20 mg/dag.
Switching a patiant to or from a Monoamine Ouidass inhibitor [MAD() Intended to treat Peychiatric Disordars: At lnat 4 days must alapon between diecornuation of an MAD intended to tinea peychiatric disordern.
and initlaton of thampy with Vortisontina to avold the risk of Sarotonin Syndrama. Corarsely, at lnas 21 dayu muxt elaps aftar atopping Vortlostine bafore atarting an MNDI inanded to treat peychiatric disardure.
nteraction
Moncamina Ouidane Inhbitors Advarse reaction, sore of wich arn sarlous ar fatal, can dwenlap in patlarts who us MAOis or wo hwrecantly bean discantinund fromn an MADi and started on a sarstonrgl:
antideprecsantaj or who hawe recantly had SSRi or SMRi tharapy discantinund prior to iniation of an MOL
Ganstonargle drug: Co-administration of Nytaro with othar druge that may aflact the sarotonangie nurofrarrittar aysarre jag. SSRis, SNRin, Trptana, Duapironn, Trarnadol, and Tryptophan praducts wte.) may
potenially Incrwass sarstonin tadelty or sarstonin syndromn. Closaly montar symptorns af samanin kyndrore if Nytaruo is co-administared with othar sarotonrgle druge. Treatmant with Nytanso and any concomitant:
sarstanargic agente should ba discontinund immadiatslylf sarstonin syndrame accur.
Other ONS active agants: No ciinically mlweant affact war ohsarved on standy-state Lithlum axposure following cs-adminxtraon with muitiple dally dosss af Mybario.
Potantial for ather drugs to affact Nytanso: Asduce Nytanso does byhalf whan a strong CYP3D6 Inhibitor [e.g. Duprapion, Fucastin, Parsastine, Qulnidina is ca-acministarad. Conidarnereasing tha Nytenco doon
whan a etrang CYP Inducar [e.g. Rifampin. Carbamazspina, Phanytain) It. co-adminixtared.
Contraindications
Vortisxatina Hydrbramide i contraindicated in Patlants with known hyparsanaltivity to Vartlcostir or any af the woplent af the drug praduct & concomitan uss of Monoamine Oodans inhibitars MAGin].
Side Etfects
Patiente taking Nytanso may aoparianon sora adverse weents such as Hyparsaraitlvlty: Clinical worsaning and suiclde riak, Sarotonin yndroma. Abnormal blanding, advalan of Mana/Hyporania, Angle coaure
Glaucoma, Hyponatremia.
Pregnancy & Lactation
The safety of Vortlcccstine in uman pragnncy hax not been astablithad. Tharefore. Vortsastne shoud not be wnd during pragnancy or in wornen Intanding to become pragnant, unees tha benafta outwnigh the
pousibie riska to the fabue. Iallabls data in animals have nhown the sacnslion of Vorticosna mataboliter In mik. i in expacted that Vortaostine willba axcreted into human mile. Decaute ritks to the mursing child cannat
on azluded, breantfwsding ls not racommanded during treatrnant with Vorticcstins.
Precautions & Warnings
Clnical Morsaning and Sulcie Ritk Apatients being trasted with antidepreacane for any indication should be monitorad apprapriataly and obearved coesly far cinical worsaning, suleidaity. and urwtual changen in
bahuwior, aspacially during the iniaifww month of a coures af drug thampy, ar at timas of doas changer, aithar incressss or decreaosr.
Sanstonin Syndroma Tha deusioprnant of a potantially lite-threataning sarotonin syndrorna has been raported with saroionargle antidspressants including Mytanso, whan used alona but more aftenwhan und
concamitantly with other sarotonargie druge Including Triptana, Tricydic Antidapmesants, Fenaryl, Lithum, Tramadol, Trypisphan, Duspirons &St. John's Mort, and with druge thait irgair matabolium of sarstonin [in
particular, MNDir, both thaos intended to traat peychlatrie disordars and alss othars, such at Linazolid and intravenous mathylans blunl.
AbnormalGleading: Tha uss of drugs that iintarfere with sarstanin nwuptake inhibition, Including Nyenso, may Inereaoe the riak of blending wvents. Concomitant uo of Aspirin, Nonatarldal
Ant-infarnmatory drugs (MNiDe), Wartarin, and othr Anticoagulante may add ta thic ritk. Activation of
Mania/Hypomania: Awith all Antidaprectant. uc Nytanas cautloutly in palsants with a hittory or farnily histary af bipolar disorder, mana, ar hypornania.
Angla Clonure Glaucoma: Tha pupilary dlation that occure follawng tha us of many Arisdepressan druge. Including Nytanss, may trigger an angie closure altack ina patient with anatomically narrow angles who doas
not have a patant irdectomy.
Hyponatramia: Hyporatrerria pccurra bacauns of treatmant with samanargle druge.
Use in Special Populations
Podiatric una [cil yeare of age). Tha safety and affectivenass af Mytaro in the padiatric papulation hawe notbean astabliahed.
Garlatrice una [>d5 yuars of age). No dons adjutrnant ie mcorrmanded on the baals of age. Renute fromn a ningle-doon paracokinatie shudy in aldarly [>65 yeare ald)we young [24 to 45 years old) nubjace damortratnd
that the pharmacainatice wers gararally timilar betwean the two aga graupe
Rsnal impairmant: No dons acjucimant it naeded.
Hapatic Impairmant. Ns docs aduttrant lcracommanded for palsants with mid or moderate hapalse mpairmant. Mytarto is not recommanded in patent with sevare hapatic Impairmant.
CYPaD6 poor mataboliaare: Tha plaema concantraton of Nytanas was. approodmately two tima highar in CYP206 poor matabolinars than in ectantlen mataboliners. In tha presancs of strong CYPSAA/20P inhlbitore, tha
upocure could patentially be highar, and a donags adjuttrant may e required.
Uss In other patient populatione: No dorn adjusimant af Nytanco ix neaded on the ba of raca, gender and ethnicity.
Overdose Effects
Tharw is limited data avallabia on Nytanso averdoas. Madical folow-up in a specialired ariranmant in recammanded.
Therapeutic Class
Garotonin-nanplnaphrina reupaka inibitor (SNRIO





Vortioxetine Hydrobromide is a prescription antidepressant used to treat major depressive disorder (MDD). It works by modulating serotonin activity in the brain—blocking and stimulating different serotonin receptors while also inhibiting serotonin reuptake.
Vortioxetine is used for depression, low mood, lack of interest, anxiety symptoms associated with depression, and cognitive symptoms like poor concentration. It may improve mood, energy, and mental clarity.





